Bezuclastinib

Name: Bezuclastinib in Nonadvanced systemic mastocytosis: Expected outcomes of therapy
Published: 2026-09-14T15:39:06-04:00

Nonadvanced systemic mastocytosis

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the second half of 2026
Last updated: September 17, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Expected outcomes of therapy

1 evidence topic · 1 source

Association of symptom improvement with an objective disease marker

“Symptom improvement significantly correlated with serum tryptase reduction” (opens the source at this quote in a new tab)
“p < 0.001, r = 0.39” (opens the source at this quote in a new tab)